Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial

Submitted: 10 September 2022
Accepted: 10 October 2022
Published: 28 November 2022
Abstract Views: 1108
PDF: 370
HTML: 72
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Common inflammatory airway disorders, such as seasonal and perennial allergic rhinitis, acute sinusitis, and nasal polyposis, can have a significant impact on patient health and quality of life. Intranasal corticosteroids are recommended as part of treatment plans for each of these illnesses because they reduce inflammation and thus symptoms. In order to compare the efficacy and safety of a new nano formulation of mometasone furoate nano-nasal spray (MF-NNS) with a commercially available nasal spray called mometasone furoate nasal spray (MFNS) for the treatment of allergic rhinitis, 20 rhinitis patients were enrolled in this randomized controlled trial (10 to 50 years). Patients were given 50 mcg MF-NNS doses in the morning and evening. This regimen was administered as a nasal spray for a 3-week efficacy and safety phase. The primary endpoints changed from baseline in the subjects’ congestion as determined by the physicians’ assessment of allergic rhinitis. Analysis of variance was used to evaluate all efficacy end points. More clinical trials have shown that MF-NNS reduces both objective and subjective markers of inflammation in adults, adolescents, and children.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Drazdauskaitė G, Layhadi JA, Shamji MH. Mechanisms of allergen immunotherapy in allergic rhinitis. Curr Allergy Asthma Rep 2021;21:1-17. DOI: https://doi.org/10.1007/s11882-020-00977-7
Baena-Cagnani CE, Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin 2010;26:2047-55. DOI: https://doi.org/10.1185/03007995.2010.487661
González-Núñez V, Valero AL, Mullol J. Impact of sleep as a specific marker of quality of life in allergic rhinitis. Curr Allergy Asthma Rep 2013;13:131-41. DOI: https://doi.org/10.1007/s11882-012-0330-z
Nielsen GD, Hansen JS, Lund RM, et al. IgE‐mediated asthma and rhinitis I: a role of allergen exposure? Pharmacol Toxicol 2002;90:231-42. DOI: https://doi.org/10.1034/j.1600-0773.2002.900502.x
Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108:S2-S8. DOI: https://doi.org/10.1067/mai.2001.115569
Eifan AO, Durham SR. Pathogenesis of rhinitis. Clin Experi Allergy 2016;46:1139-51. DOI: https://doi.org/10.1111/cea.12780
Berkowitz R, Roberson S, Zora J, et al. (eds). Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy & Asthma Proceedings; OceanSide Publications: 1999. DOI: https://doi.org/10.2500/108854199778553037
Scadding GK. Optimal management of allergic rhinitis. Archiv Dis Childhood 2015;100:576-82. DOI: https://doi.org/10.1136/archdischild-2014-306300
Carr WW, Ratner P, Munzel U, et al. (eds). Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy & Asthma Proceedings; 2012. DOI: https://doi.org/10.2500/aap.2012.33.3626
Komi DEA, Mortaz E, Amani S, et al. The role of mast cells in IgE-independent lung diseases. Clin Rev Allergy Immunol 2020;58:377-87. DOI: https://doi.org/10.1007/s12016-020-08779-5
Far J, Abdel-Haq M, Gruber M, Abu Ammar A. Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery. ACS Omega 2020;5:7432-9. DOI: https://doi.org/10.1021/acsomega.0c00111
Williamson I, Benge S, Barton S, et al. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial. BMJ 2009;339. DOI: https://doi.org/10.3310/hta13370
Salib R, Drake‐Lee A, Howarth P. Allergic rhinitis: past, present and the future. Clin Otolaryngol Allied Sci 2003;28:291-303. DOI: https://doi.org/10.1046/j.1365-2273.2003.00706.x

How to Cite

Mehmood, Y., Shahid, H., Tariq, A., & Ali, S. O. (2022). Efficacy and safety of a new mometasone furoate nasal spray formulation in patients with acute rhinosinusitis: a randomized clinical trial. Italian Journal of Medicine, 16(1). https://doi.org/10.4081/itjm.2022.1533

List of Cited By :

Crossref logo